We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-8.74%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$372M
AUM Growth
-$150M
Cap. Flow
+$204K
Cap. Flow %
0.05%
Top 10 Hldgs %
78.05%
Holding
23
New
2
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$28.4M
2
ANAB icon
AnaptysBio
ANAB
+$10.1M
3
RNAM
Avidity Biosciences
RNAM
+$4.1M
4
KYNB
Kyntra Bio
KYNB
+$3.46M

Top Sells

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$28M
2
VRDN icon
Viridian Therapeutics
VRDN
+$4.26M
3
SCPH
scPharmaceuticals
SCPH
+$3.67M
4
FVAM
5:01 Acquisition Corp
FVAM
+$3.65M
5
ARVN icon
Arvinas
ARVN
+$3.37M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CINC
1
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$60.7M 16.31%
4,937,646
– –
TRDA icon
2
Entrada Therapeutics
TRDA
$282M
$59.6M 16.02%
4,408,379
– –
VOR icon
3
Vor Biopharma
VOR
$1.16B
$42.3M 11.37%
318,086
– –
RLYB icon
4
Rallybio
RLYB
$84.6M
$24.5M 6.59%
466,341
– –
IDYA icon
5
IDEAYA Biosciences
IDYA
$3.41B
$21.7M 5.84%
1,196,298
– –
PEAR
6
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$19.8M 5.31%
16,744,113
-159,490
-0.9% -$335K
SCPH
7
DELISTED
scPharmaceuticals
SCPH
$19.6M 5.27%
2,734,852
-600,000
-18% -$3.67M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$8.89B
$15.8M 4.24%
862,286
– –
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$14.8M 3.97%
665,555
+275,000
+70% +$4.1M
IRON icon
10
Disc Medicine
IRON
$2.93B
$11.7M 3.15%
588,442
+570,959
+3,266% +$28.4M
ANAB icon
11
AnaptysBio
ANAB
$1.59B
$11.1M 2.98%
+357,733
New +$10.1M
ARVN icon
12
Arvinas
ARVN
$520M
$10.9M 2.94%
320,000
-80,000
-20% -$3.37M
IMPL
13
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$10.8M 2.91%
2,884,791
– –
COGT icon
14
Cogent Biosciences
COGT
$6.64B
$9.14M 2.46%
790,440
– –
VRDN icon
15
Viridian Therapeutics
VRDN
$2.13B
$8.76M 2.35%
300,000
-184,891
-38% -$4.26M
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.23M 2.21%
384,626
-124,221
-24% -$2.65M
PHVS icon
17
Pharvaris
PHVS
$2.25B
$6.61M 1.78%
587,600
– –
JANX icon
18
Janux Therapeutics
JANX
$934M
$5.88M 1.58%
446,266
– –
QTTB icon
19
Q32 Bio
QTTB
$450M
$5.72M 1.54%
251,996
– –
KYNB
20
Kyntra Bio
KYNB
$27.4M
$3.61M 0.97%
+9,023
New +$3.46M
CDTX
21
DELISTED
Cidara Therapeutics
CDTX
$858K 0.23%
56,726
– –
AKUS
22
DELISTED
Akouos Inc
AKUS
– –
-4,135,784
Closed -$28M
FVAM
23
DELISTED
5:01 Acquisition Corp
FVAM
– –
-365,126
Closed -$3.65M

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q4 2022 Portfolio in Review

As of Q4 2022, 5AM Venture Management held 23 positions worth $372M, down 29% from $522M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

5AM Venture Management's Q4 2022 filing shows 2 new, 2 increased, 5 reduced and 2 closed positions. Its largest new stake was AnaptysBio: 357,733 shares worth $11.1M. The largest sale was Akouos Inc, an estimated $28M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • 5AM Venture Management's largest Q4 2022 buy was AnaptysBio: 357,733 shares worth $11.1M.
  • 5AM Venture Management added most to Disc Medicine in Q4 2022, an estimated $28.4M increase.
  • 5AM Venture Management's biggest Q4 2022 reduction was Viridian Therapeutics, cutting an estimated $4.26M.
  • 5AM Venture Management fully exited Akouos Inc in Q4 2022, selling an estimated $28M.
  • 5AM Venture Management's ten largest holdings make up 78% of its $372M portfolio in Q4 2022.
  • 5AM Venture Management opened 2 new positions and closed 2 in Q4 2022.
  • 5AM Venture Management's portfolio value fell 29% quarter-over-quarter to $372M.

Based on 5AM Venture Management's 13F filing for Q4 2022, filed 14 Feb 2023.